Feasibility of Long-Acting Combination HIV and Pregnancy Prevention Implant Demonstrated in Mouse Model

February 13-16, 2022; Virtual
Implant sustained release of ARV above viral replication inhibition thresholds in a mouse model; no difference in ARV release when coformulated with either of 2 contraceptives.
Format: Microsoft PowerPoint (.ppt)
File Size: 146 KB
Released: February 18, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Cepheid
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings